Silexion Therapeutics ( ($SLXN) ) has shared an announcement. On January 6, 2026, Silexion Therapeutics released a CEO letter to shareholders ...
Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced interim results from two Phase 1/2a clinical trials of ARO-INHBE and ARO-ALK7, the company’s investigational RNA interference (RNAi) ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback